B. Riley Securities Rates Nutex Health (NUTX) buy

B. Riley Securities reiterated its buy rating on NUTX with a $290 price target, a 79.37% upside from the current price.

By EarningsIQ Research Desk · Published Jun 26, 2026, 12:01 PM EDT · Updated Jun 27, 2026, 2:01 AM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

B. Riley Securities rated Nutex Health Inc. ($NUTX) "buy" with a $290 price target on June 26, 2026.

Since the rating, $NUTX is up 16.3% after 1 week, down 10.6% after 1 month and up 11.8% to date (from the $166.40 close on Jun 26, 2026).

NUTX Nutex Health Inc.

$186.10 +25.58% year to date

Daily close · Oct 16, 2026

Key Points

B. Riley Securities reiterated its buy rating on NUTX on June 26, 2026, setting a $290 price target.
B. Riley Securities's $290 price target implies 79.37% upside from Nutex Health Inc.'s ($NUTX) current $161.68 share price.
Shares of NUTX traded near $161.68 on Friday, reflecting analysts' ongoing positive outlook.
Recent insider buying activity includes CEO Thomas Vo purchasing 75,747 shares on May 28, 2026.

Get $NUTX trade alerts by text

We text you when insiders, Congress or big funds trade $NUTX. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Nutex Health Inc. alert may contain errors. Disclosures

B. Riley Securities reiterated its buy rating on NUTX on June 26, 2026, maintaining a price target of $290. This reflects continued confidence in the company's potential.

Analyst rating track record

B. Riley Securities vs. the S&P 500

YTD return +10.74% hypothetical

All-time return +52.81% S&P 500 +17.95%

vs. S&P 500 +34.86% ahead of the index

Hypothetical returns from B. Riley Securities's disclosed trades, not real profit or advice. How we model this.

Other Institutional Activity in NUTX

Several institutional investors have adjusted their positions in NUTX. BlackRock, Inc. grew its holdings by 97,802 shares, ending with 379,355 shares valued at about $36.1 million, a 34.7% increase. Pertento Partners LLP added 49,548 shares, bringing its total to 373,970 shares worth $35.5 million, marking a 15.3% rise. Vanguard Capital Management LLC opened a new position with 219,131 shares, valued at approximately $20.8 million. American Century Companies Inc increased its stake by 71,409 shares to 203,450 shares, valued at $19.3 million, a 54.1% increase. Meanwhile, Topline Capital Management, LLC reduced its holdings by 497,694 shares, leaving it with 177,800 shares worth $16.9 million, a 73.7% decrease.

Nutex Health Inc. Stock Down 22.6%

Shares of NUTX traded near $161.68 on Friday. The stock has experienced significant institutional interest, reflecting a positive outlook from major funds. The company's stock performance is closely watched by investors, given the recent analyst ratings and insider activities.

12-month forecast

$NUTX price target

Nutex Health Inc. daily closes and this analyst's $290 target. Not advice.

Insider Buying and Selling at Nutex Health Inc.

Recent insider activity at NUTX includes several purchases. On May 28, 2026, CEO Thomas Vo acquired 75,747 shares. Earlier, on April 23, 2026, insiders including Cheryl Yvonne Grenas, Frank Jaumot, Michael Lee Reed, and Scott Saunders each bought 823 shares. Kelvin Spears also purchased 2,519 shares on June 4, 2026. These transactions suggest confidence from those within the company.

Analysts Set New Price Targets

On June 26, 2026, B. Riley Securities reiterated its buy rating on NUTX with a price target of $290. Earlier in June, Lake Street initiated coverage with a buy rating and a $235 target. Maxim Group maintained its buy rating multiple times throughout 2025, with targets ranging from $75 to $225. The consensus among analysts remains optimistic, with a strong buy recommendation and a mean target price reflecting expected growth.

Bottom Line

The reiteration of the buy rating by B. Riley Securities, along with significant institutional activity and insider buying, highlights the market's positive sentiment towards NUTX. Investors closely monitor these updates, understanding that 13F filings and analyst ratings are historical and may not reflect current positions. Nevertheless, the data provides valuable insights into the company's perceived potential.